跳至主要内容
临床试验/NCT01934478
NCT01934478已完成不适用

Study on Human Epidermal Growth Factor 2 (Her2) Expression Changes in Human Breast Cancer After Radiotherapy

Qingdao Central Hospital1 个研究点 分布在 1 个国家目标入组 5 人开始时间: 2013年8月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
5
试验地点
1
主要终点
Her2 changes during radiotherapy

研究概览

简要总结

Based on fundamental study (in Vitro and in Vivo, Pro. Jianjian Li), Her2 expression would be changed from negative to positive by cancer irradiation with liner-accelerator at dose 6GY or up. The propose of this study is to reveal the irradiation result on Her2 expression in human breast cancer.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • histological confirmed advanced breast cancer
  • cancer sample can be obtained by fine needle biopsy
  • IHC and FISH confirmed Her2 negative
  • radiotherapy indication for local residual cancer

排除标准

  • no radiotherapy indication
  • patient refuse

结局指标

主要结局

Her2 changes during radiotherapy

时间窗: every week up to 6 weeks

biopsy is obtained by fine needle biopsy,Her2 is checked by Immunohistochemistry (IHC) and Fluorescence in situ hybridization (FISH).

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Youxin Ji

Chief, Department of Oncology

Qingdao Central Hospital

研究点 (1)

Loading locations...

相似试验